Blog
About

5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy.

          Related collections

          Author and article information

          Journal
          Cancer Chemother. Pharmacol.
          Cancer chemotherapy and pharmacology
          Springer Nature
          1432-0843
          0344-5704
          May 2016
          : 77
          : 5
          Affiliations
          [1 ] Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
          [2 ] Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan. khotta@okayama-u.ac.jp.
          [3 ] Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikatacho, Kitaku, Okayama, 700-8558, Japan. khotta@okayama-u.ac.jp.
          [4 ] Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan.
          [5 ] Department of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, Matsuyama, Japan.
          [6 ] Department of Respiratory Medicine, NHO Iwakuni Medical Center, Iwakuni, Japan.
          [7 ] Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.
          [8 ] Department of Respiratory Medicine, Chugoku Central Hospital, Fukuyama, Japan.
          [9 ] Department of Respiratory Medicine, NHO Fukuyama Medical Center, Fukuyama, Japan.
          [10 ] Department of Respiratory Medicine, Japanese Red Cross Kobe Hospital, Kobe, Japan.
          [11 ] Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
          [12 ] Department of Hematology and Oncology, Okayama University Hospital, 2-5-1, Shikatacho, Kitaku, Okayama, 700-8558, Japan.
          Article
          10.1007/s00280-015-2910-9
          10.1007/s00280-015-2910-9
          27029623

          Lung cancer, Response, Skin rash, Afatinib

          Comments

          Comment on this article